Structure Therapeutics announced that its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) has been officially scheduled for the second quarter of 2026.

This meeting aims to discuss Phase II trial data and provide guidance for the subsequent Phase III clinical trial protocol. Meanwhile, the company has confirmed that the launch plan for its Phase III clinical trial is still proceeding according to the original schedule, with expectations to begin in the second half of 2026. This progress marks a critical step forward in the company's core R&D project, laying an important foundation for the future development of its main candidate drug.